Oruka Therapeutics Inc (ORKA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -31,820 | -105,433 | -75,850 | -45,573 | -20,999 |
| Depreciation Amortization | -403 | -4,920 | -4,285 | -3,265 | -1,781 |
| Accounts payable and accrued liabilities | 2,502 | -5,320 | -7,268 | 1,202 | -5,122 |
| Other Working Capital | 1,534 | -2,555 | -5,925 | -5,323 | -3,034 |
| Other Operating Activity | 4,609 | 30,018 | 27,712 | 8,945 | 10,067 |
| Operating Cash Flow | $-23,578 | $-88,210 | $-65,616 | $-44,014 | $-20,869 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -73 | -209 | -146 | -47 | -13 |
| Purchase Of Investment | -90,834 | -520,959 | -419,972 | -152,289 | -44,290 |
| Sale Of Investment | 76,470 | 424,423 | 345,395 | 200,062 | 87,169 |
| Investing Cash Flow | $-14,437 | $-96,745 | $-74,723 | $47,726 | $42,866 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 40,600 | 671 | 109 | 109 | N/A |
| Other Financing Activity | 0 | 169,644 | 169,908 | 0 | 0 |
| Financing Cash Flow | $40,600 | $170,315 | $170,017 | $109 | $N/A |
| Beginning Cash Position | 46,935 | 61,575 | 61,575 | 61,575 | 61,575 |
| End Cash Position | 49,520 | 46,935 | 91,253 | 65,396 | 83,572 |
| Net Cash Flow | $2,585 | $-14,640 | $29,678 | $3,821 | $21,997 |
| Free Cash Flow | |||||
| Operating Cash Flow | -23,578 | -88,210 | -65,616 | -44,014 | -20,869 |
| Capital Expenditure | -73 | -209 | -146 | -47 | -13 |
| Free Cash Flow | -23,651 | -88,419 | -65,762 | -44,061 | -20,882 |